Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
12:42pm, Wednesday, 06'th May 2026
The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization pow
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
04:44am, Thursday, 30'th Apr 2026
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
12:00pm, Wednesday, 29'th Apr 2026
Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on Apr
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
01:25pm, Tuesday, 28'th Apr 2026
Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing p
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
01:30am, Saturday, 25'th Apr 2026
Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.
Press Release: Sanofi successfully prices 2.3 billion of bond issue
02:30pm, Friday, 24'th Apr 2026
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
02:30pm, Thursday, 23'rd Apr 2026
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
01:46pm, Thursday, 23'rd Apr 2026
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
10:20am, Thursday, 23'rd Apr 2026
Sanofi beats Q1 estimates as Dupixent and new drugs fuel double-digit growth, with strong sales and earnings gains supporting its 2026 outlook.
Sanofi Posts Higher Sales Amid Leadership Transition
02:08am, Thursday, 23'rd Apr 2026
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
Sanofi's first quarter earnings edges past estimates ahead of CEO change
01:35am, Thursday, 23'rd Apr 2026
French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for its blockbuster asthma and eczema drug Dupixent.
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
01:05am, Wednesday, 22'nd Apr 2026
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of st
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
01:00am, Wednesday, 22'nd Apr 2026
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target a
